EGFR and breast carcinoma: When treated with the anti-Her-1 monoclonal antibody cetuximab, the anti-Her-2 monoclonal antibody trastuzumab or the dual Her-1/2 inhibitor lapatinib, TXNIP mRNA and protein levels were increased in breast cancer cells.